Fig. 2
Potentiation effects in other cancer cells and pre-treatment of ICRF193. Human breast cancer cells, (a) MCF7 and (b) T47D cells, were treated with etoposide in the presence or absence of 200 nM ICRF193 for 72 h. (c) The timeline of the pre-treatment experiment. First, the cells were treated with 10 µM ICRF193 for 30 min, then several concentrations of etoposide were added to each well, followed by 1 h incubation. After washing, the cells were cultured for 72 h in fresh medium. (d) Cell viability assay result for etoposide with or without pre-treatment with 10 µM ICRF193 treatment. The-y axis indicates the percent viability of the cells. The x axis indicates the concentrations of etoposide. The error bars indicate the standard deviation from three independent experiments.
